US Has Opportunity To Lead On Ophthalmic Biosimilars

Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report

 
• By Dave Wallace
Turning Point Sign
Cardinal Health says 2022 will be a turning point for US biosimilars • Source: YAY Media AS / Alamy Stock Photo

More from Biosimilars

More from Products